In ESCC patients undergoing neoadjuvant chemotherapy, the PD-L1 status of tumor cells in positive LN tissues and the FOXP3/CD8 ratio in primary tumors are identified as prognostic factors for overall clinical outcomes (168). This evidence concerns the gene CD8A and neoplasm.